Success Stories: Research Instructor in the Field of Pharmaceutical Sciences in Colorado Received an EB-1A Approval
Client’s Testimonial:
Thank you again for your help. I have already recommend couple of my friends.
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Research Instructor
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Colorado
Approval Notice Date: July 27, 2014
Processing Time: 6 months and 4 days
Case Summary:
For this EB-1A case, we had the privilege of working with a Research Instructor, who has made substantial contributions and garnered international acclaim in the field of Pharmaceutical Sciences. In his research endeavors, our client has specialized in drug discovery, drug delivery, and biopharmaceutics. He has marked his career with the discovery of ovel antibiotics that are capable of treating drug resistant bacterial infections and the delivery of drugs to the eye with greater bioavailability. The originality of our client’s work has culminated in the authorship of 8 peer-reviewed scientific manuscripts that were published in the top journals of his field and an issued patent. At the time of filing his case, his publications had been cited 81 times by researchers worldwide, demonstrating the global scientific community’s heavy reliance upon his work. Furthermore, his work has been presented and discussed at internationally renowned conferences. The major significance of his work was endorsed by an independent recommender, who stated, “These advances in prodrugs that [Client] pioneered have a profound effect on the pharmaceutical industry, both in US concerns and abroad. Treatment of the posterior eye diseases have been hobbled by the ocular barriers that they have reduced the efficacy of topical drugs. The only way to handle this previously is through the aforementioned intravitreal method, or repeated applications of topical drugs like eye drops. With the advent of these new transporter-facilitated drugs, we can expect to see our ocular treatments become heavily improved, as well as the chance for complications diminish.” Ultimately, our client’s outstanding findings have been implemented by other experts among his field. Additionally, our client has been invited to judge the work of his colleagues and other forerunners in his field, and he has served as a manuscript reviewer for several internationally circulated journals. In total, he has reviewed 17 articles thus far. With the extensive and thorough documentation that we provided, we exhibited the immeasurable value of our client’s contributions to the current state of pharmaceutical research and development. In demonstrating the extraordinary ability of our client and international acclaim for his research, we were able to prove that he has risen to the very top of his field of endeavor. We were met with success when his EB-1A petition was approved in 6 months and 4 days.